iPSirius
iPSirius SAS is an immuno-oncology firm focused on developing IPVAC 1.0, a novel therapeutic cancer vaccine. Leveraging the antigenic overlap between iPSCs and cancer stem cells (CSCs), iPSirius aims to combat relapse and metastatic progression in cancer patients.
LinkedIn URL
Location
Official Website
Find more companies like iPSirius
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
By using this site, you agree to our Terms of Service.